LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Listă Acțiuni・Incyte Corp
Search

Incyte Corp

Închisă

SectorSănătate

99.05 -1.26

Cumpărare

Preț actualizat 12 mai 2026, 19:59 UTC

CumpărăVinde

Rezumat

Modificarea prețului

24h

Curent

Minim

98.35

Maxim

101.08

Indicatori cheie

By Trading Economics

Venit

4.1M

303M

Vânzări

-234M

1.3B

P/E

Medie Sector

14.17

49.8

EPS

1.81

Marjă de profit

23.834

Angajați

2,844

EBITDA

-47M

367M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+10.09% upside

Dividende

By Dow Jones

Următoarele câștiguri

28 iul. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

993M

20B

Deschiderea anterioară

100.31

Închiderea anterioară

99.05

Sentimentul știrilor

By Acuity

35%

65%

99 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

59.52 / 62.66 Suport & Rezistență

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2026, 22:50 UTC

Câștiguri

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

DJ

Citește

12 mai 2026, 22:49 UTC

Câștiguri

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

DJ

Citește

12 mai 2026, 22:32 UTC

Câștiguri

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

DJ

Citește

12 mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

DJ

Citește

12 mai 2026, 22:57 UTC

Market Talk
Câștiguri

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

DJ

Citește

12 mai 2026, 22:26 UTC

Câștiguri

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

DJ

Citește

12 mai 2026, 22:25 UTC

Câștiguri

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

DJ

Citește

12 mai 2026, 22:25 UTC

Câștiguri

Aristocrat Leisure Interim Dividend A$0.50/Security

DJ

Citește

12 mai 2026, 22:24 UTC

Câștiguri

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

DJ

Citește

12 mai 2026, 22:23 UTC

Câștiguri

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

DJ

Citește

12 mai 2026, 22:23 UTC

Câștiguri

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

DJ

Citește

12 mai 2026, 22:19 UTC

Câștiguri

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

DJ

Citește

12 mai 2026, 22:14 UTC

Câștiguri

CBA: Business Lending Continued to Grow Above System>CBA.AU

DJ

Citește

12 mai 2026, 22:14 UTC

Câștiguri

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

DJ

Citește

12 mai 2026, 22:13 UTC

Câștiguri

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

DJ

Citește

12 mai 2026, 22:12 UTC

Câștiguri

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

DJ

Citește

12 mai 2026, 22:12 UTC

Câștiguri

CBA 3Q New Home Loan Funding A$45B>CBA.AU

DJ

Citește

12 mai 2026, 22:11 UTC

Câștiguri

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

DJ

Citește

12 mai 2026, 22:11 UTC

Câștiguri

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

DJ

Citește

12 mai 2026, 22:10 UTC

Câștiguri

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

DJ

Citește

12 mai 2026, 22:09 UTC

Câștiguri

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

DJ

Citește

12 mai 2026, 22:09 UTC

Câștiguri

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

DJ

Citește

12 mai 2026, 22:08 UTC

Câștiguri

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

DJ

Citește

12 mai 2026, 22:07 UTC

Câștiguri

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

DJ

Citește

12 mai 2026, 22:06 UTC

Câștiguri

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

DJ

Citește

12 mai 2026, 22:06 UTC

Câștiguri

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

DJ

Citește

12 mai 2026, 22:05 UTC

Câștiguri

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

DJ

Citește

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

DJ

Citește

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

DJ

Citește

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

DJ

Citește

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

10.09% sus

Prognoză pe 12 luni

Medie 109.13 USD  10.09%

Maxim 135 USD

Minim 75 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

8

Cumpărare

8

Păstrare

1

Vânzare

Ținând cont de 17 analiști care au acordat evaluări ale acțiunilor Incyte Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Termen scurt

Bullish Evidence

Bullish events outweigh bearish events.

Termen mediu

Bearish Evidence

All events are bearish.

Termen lung

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

99 / 346 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Alte acțiuni din sector

LLY

Eli Lilly and Co.

987.98

↑ +2.24%

JNJ

Johnson and Johnson

224.37

↑ +1.35%

ABBV

AbbVie Inc

207.85

↑ +2.48%

UNH

UnitedHealth Group Inc

396.24

↑ +3.1%

AZN

AstraZeneca PLC

184.48

↑ +1.46%
help-icon Live chat